Vision Monday Covers “Optometrist of the Year”

Orginally published in Vision Monday

Read at Vision Monday

California Optometric Association Names David C. Ardaya, OD, Optometrist of the Year

By Staff
Tuesday, April 11, 2023 12:15 AM

WHITTIER, Calif.—The California Optometric Association (COA) has named David C. Ardaya, OD, Optometrist of the Year. Dr. Ardaya is president of Golden Optometric Group in Whittier, California, and a practicing optometrist there. He is also a senior managing optometrist of TeamVision and COA’s chair for the Health Care Delivery Systems Team. This award recognizes Dr. Ardaya’s impact on the visual welfare of the public, which include published articles and media appearances providing education on the essential services that doctors of optometry provide.

Dr. Ardaya’s advocacy on behalf of the profession resulted in the reinstatement of coverage for adult eyeglasses in the Medi-Cal program. Dr. Ardaya said, “I’m deeply grateful and humbled to receive this award. The California Optometric Association has done so much to improve the optometric profession and promote access to care for patients. I’m excited to continue this journey with my friends at the COA.”

Candi Kimura, OD, president, California Optometric Association, said, “COA is pleased to recognize Dr. David Ardaya’s commitment to improving health care systems so that more Californians have access to eyecare. In addition to managing multiple practices, Dr. Ardaya has provided expert advice to his colleagues to improve business operations and develop medical contacts.

“Besides being a tremendous resource for his fellow optometrists, Dr. Ardaya volunteers regularly outside of optometry including serving meals to those in need, volunteering for the Special Olympics, and has helped with numerous vision screenings at hospitals and schools. He has also been involved in fundraising for the American Diabetes Association and juvenile diabetes research,” Dr. Kimura said.

Dr. Ardaya received his Bachelor of Science in Physiological Sciences from the University of Arizona, his Doctor of Optometry degree with distinction from Pacific University and his Master of Health Administration from the University of Southern California. In 2009, Dr. Ardaya was awarded the “Young Optometrist of the Year” by the California Optometric Association. He is fluent in Spanish and began practicing optometry at Golden Optometric in Whittier in 2005, where he has served the community for over 18 years.

optometrist of the year awarded to Dr. David Ardaya

Whittier Doctor Ardaya Given Top Award for California

We are incredibly proud to announce that our very own Dr. David Ardaya was selected as the 2022 Optometrist of the Year by the California Optometric Association! He received the surprise award in San Francisco at the annual COA House of Delegates meeting.

Dr. Ardaya is an active member of the COA and many other aspects of the eyecare field and a published author and subject of articles on leading developments in the industry.

In 2009, Dr. Ardaya was awarded the “Young Optometrist of the Year” by the California Optometric Association.

“I’m deeply grateful and humbled to receive this award. The California Optometric Association has done so much to improve the optometric profession and promote access to care for patients. I’m excited to continue this journey with my friends at the COA.”

David C. Ardaya

O.D., M.H.A., President of Whittier office, Golden Optometric

Dr David Ardaya, awarded optometrist of the year

Dr. David Ardaya with his wife, doctor Ivy Lin, OD and COA representative(above) and Dr Ardaya receiving the award, surrounded by his wife, Ivy Lin, OD and their two children (below).

Dr David Ardaya, awarded optometrist of the year

Read the Vision Monday article to learn more

Dr David Ardaya, awarded optometrist of the year

Optometrists May Give Coronavirus Vaccines

When coronavirus vaccines are ready, dentists, optometrists may give shots

These medical professionals are seeking permission to vaccinate patients against Covid-19 and other diseases to take pressure off of primary care doctors.

Report on NBC quotes Golden Optometric Whittier’s doctor David Ardaya.

Our whole hope is to assist our nation in regaining its health and in returning to a sense of normal.
David Ardaya, O.D.

optometrists may also vaccinate for coronavirus

The Best Transitions Ever

See Better Indoors & Outdoors





The Best Overall Photochromic Lens*


• Activation Speed Up To 30% Faster than Transitions® Signature® lenses
• Fade Back 3 Minutes Faster than Transitions® Signature® lenses
• 9 Out Of 10 Patients Love And Intend To Repurchase Transitions® Signature® GEN 8™ Lenses**

*Based on achieving the highest weighted composite score, among main everyday photochromic lenses across measurements of key photochromic performance attributes, weighted by their relative importance to consumers.
**Source: Jan – Sept 2018 US Consumer Brand Tracking, eye glasses wearers (18-69 y/o), n=595.



Fully clear indoors

No tint indoors, just clear lenses

Even darker outdoors

Darker than Transitions® Signature® VII, offering even more protection

Faster activation & fade back to clear

Up to 30% faster activation1 3 minutes faster fade back2 versus Transitions® Signature®

Ultimate eye protection

Blocks 100% UVA UVB and filters harmful blue light indoors & outdoors

New Contact Lens Technology: ACUVUE OASYS® with Transitions

Light Adaptive Contact Lens

First of Its Kind Technology


Available early at Golden Optometric – West Covina.

Exciting news here at Golden Optometric-West Covina. We are one of the first to have the ACUVUE OASYS® Transition contact lenses in the county and we are so excited to show you!

Introducing the first-of-its-kind light-adaptive contact lens.The first and only contact lens that seamlessly adapts to changing light, providing all-day soothing vision.

ACUVUE® OASYS with Transitions™ activates in less than a minute and quickly fades from dark to clear when going from outdoors to indoors.

Call us to schedule your Contact Lens fitting today at (626) 962-5868


ACUVUE® OASYS with TransitionsTM is a first-of-its-kind1contact lens for contact lens wearers. These lenses combine a proven ACUVUE® OASYS (senofilcon A) material with Transitions™ Light Intelligent Technology™. The result is a lens that seamlessly adapts to changing light, providing all-day, soothing vision2,3*

The Biggest Problem Right In Front of Your Eyes

Golden Optometric Group Seeks Participants for Clinical Trial


12 December 2018

David C. Ardaya, O.D., M.H.A
Phone: (562) 692-1208

Whittier, California — Nearsightedness or myopia is often thought to be simply an annoyance that requires children to wear glasses or contact lenses, but this condition is far from benign. It is now well established that people with myopia have an elevated risk of developing potentially blinding conditions such as glaucoma, choroidal neovascularization, and retinal detachment.1,2 Even more alarming is the dramatic rise in the prevalence of myopia that we have seen around the world over the last 45 years.3It is now estimated that 5 billion people will have myopia by 2050.4

Myopia has increased so much in some East Asian countries that 80-90% of school-aged children are affected.5,6 In China alone, over 450 million people are myopic prompting Chinese President Xi Jinping earlier this year to issue a directive to protect children’s eyesight that includes increased regulations and control over internet video games.7

Based on foundational technology developed with academic partners, SightGlass Vision, Inc. is running a clinical trial for FDA approval for spectacles that have been designed to correct myopia as well as reduce the rate of myopic progression in children. Currently available glasses in the United States only correct myopia, but do not help prevent it from getting worse.

Golden Optometric is one of 14 clinical sites actively recruiting participants in North America.

Study participants must be 6- to 9-years old. The study involves using the study glasses for up to three years. Trial participants will be able to choose from a variety of eye glass frames and will be asked to use one of three types of lenses instead of their normal glasses.

Children will be assessed by a study doctor and, if suitable, be invited to participate in the study and to attend up to 14 further visits over three years. The glasses used in the study are provided at no cost and participants will be paid a small reimbursement for time and travel expenses. Children participating will also receive comprehensive eye care at no cost during the time they are in the study.

Parents who are interested in having their 6- to 9-year-old child with myopia participate in this clinical trial can find more information at or contact Dr. Ardaya with Golden Optometric Group at (562) 692-1208.

About Golden Optometric Group: Golden Optometric Group was founded in 1959 by Sheldon M. Golden,OD following his graduation from U.C. Berkeley School of Optometry. In 1972, Dr. Sheldon Golden moved his practice to its current location of 11245 E Washington Blvd. in Whittier, CA and later opened a second location in West Covina. Dr. David Ardaya is a partner and the current president of Golden Optometric Group’s Whittier location and is actively involved in clinical research, acting as the principal investigator multiple clinical trials.Through his leadership he strives to provide personalized and compassionate care to all patients. Dr. Ardaya is a past President of the Orange County Optometric Society and was recognized as Young Optometrist of the Year in 2009 by the California Optometric Association.

Disclaimer: This press release contains “forward-looking information”, including “future oriented financial information” and “financial outlook”, under applicable securities laws (collectively referred to herein as forward-looking statements). Except for statements of historical fact, information contained herein constitutes forward-looking statements and includes, but is not limited to, the (i) projected financial performance of the Company; (ii) completion of, and the use of proceeds from, the sale of the shares being offered hereunder; (iii) the expected development of the Company’s business,projects and joint ventures; (iv) execution of the Company’s vision and growth strategy, including with respect to future M&A activity and global growth;(v) sources and availability of third-party financing for the Company’s projects; (vi) completion of the Company’s projects that are currently underway, in development or otherwise under consideration; and (vi) future liquidity, working capital, and capital requirements. Forward-looking statements are provided to allow potential investors the opportunity to understand management’s beliefs and opinions in respect of the future so that they may use such beliefs and opinions as one factor in evaluating an investment.

These statements do not guarantee future performance and undue reliance should not be placed on them. Such forward-looking statements necessarily involve known and unknown risks and uncertainties, which may cause actual performance and financial results in future periods to differ materially from any projections of future performance or result expressed or implied by such forward-looking statements.

Although forward-looking statements contained in this press release are based upon what management of the Company believes are reasonable assumptions, there can be no assurance that forward-looking statements will prove to be accurate, as actual results and future events could differ materially from those anticipated in such statements. The Company undertakes no obligation to update forward-looking statements if circumstances or management’s estimates or opinions should change except as required by applicable securities laws. The reader is cautioned not to place undue reliance on forward-looking statements.


  1. Mitchell P, Hourihan F, Sandbach J, Wang JJ. The relationship between glaucoma and myopia: The Blue Mountains Eye Study. Ophthalmol 1999; 106(10): 2010-2015.
  2. Robboy MW, Hilmantel G, Tarver ME, Eydelman MB. Assessment of Clinical Trials for Devices Intended to Control Myopia Progression in Children. Eye & Contact Lens 2018;0: 1–8.
  3. Walline JJ, Robboy MW, Hilmantel G, Tarver ME, Afshari NA, Dhaliwal DK, Morse CL, Quinn CJ, Repka MX, Eydelman MB. Food and Drug Administration, American Academy of Ophthalmology, American Academy of Optometry, American Association for Pediatric Ophthalmology and Strabismus, American Optometric Association,American Society of Cataract and Refractive Surgery, and Contact Lens Association of Ophthalmologists Co-Sponsored Workshop: Controlling the Progression of Myopia: Contact Lenses and Future Medical Devices. Eye Contact Lens. 2018;44(4):205-211.
  4. Holden BA, Fricke TR,Wilson DA, Jong M, Naido KS, Sankaridurg P, Wong TY, Naduvilath TJ, Resnikoff S. Global prevalence of myopia and temporal trends from 2000 through 2050.Ophthalmol 2016;123: 1036-1042.
  5. Morgan IG, Ohno-Matsui K, Saw SM. Myopia. Lancet 2012;379: 1739-48.
  6. Dolgin, E. The Myopia Boom. Nature 2015; 519(7543): 276–278.
  7. Roantree AM, Glenn E. Tencent Loses $20 Billion in Value After China Attacks Myopia With Gaming Curbs.Reuters (2018, August 30). Retrieved from